Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.

Blurting out 'Eureka' in the afternoon of Wednesday, October 8, 2025, indicated how excited I became on receiving a call ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that new data from across ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its advancing oncology pipeline will be shared in seven abstracts at the European Society for Medical Oncology ...

Why are we able to recall only some of our past experiences? A new study at the RIKEN Center for Brain Science in Japan has ...

Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types ...

OSLO, Norway, Oct. 15, 2025 /PRNewswire/ — Photocure ASA (OSE: PHO ), the Bladder Cancer Company, announces that it has entered into a partnership with Intelligent Scopes Corporation (ISC) to develop ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

OSR Holdings, Inc. (NASDAQ: OSRH) today announced that it has executed a definitive agreement to acquire Woori IO Co., Ltd. ( ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated biotechnology company with marketed products and a pipeline of development candidates, today announced ...